title: Protease-Sensitive Inhibitory Activity of Cell-free Supernatant of Lactobacillus crispatus 156 Synergizes with Ciprofloxacin, Moxifloxacin and Streptomycin Against Pseudomonas aeruginosa: An In Vitro Study.
abstract: Ciprofloxacin and streptomycin are frequently prescribed for the treatment of medical conditions originating due to infection by Pseudomonas aeruginosa. However, fluoroquinolone administration has been linked to the outgrowth of Clostridium difficile pathogen, especially in immunocompromised patients. Secondly, frequent administration of antibiotics may lead to development of resistance in the pathogens. Thus, there is a need to explore innovative adjunct therapies to lower the therapeutic doses of the antibiotics. Herein, we evaluated the synergism, if any, between conventional antibiotics and the cell-free supernatant (CFS) of vaginal Lactobacillus crispatus 156 against P. aeruginosa MTCC 741. L. crispatus 156 was isolated from the human vaginal tract, and its CFS had broad-spectrum antimicrobial activity against various Gram-positive and Gram-negative pathogens, including P. aeruginosa. The inhibitory substance present in the CFS completely lost its activity after treatment with proteinases and was resistant to temperatures up to 80 °C and pH ranging from 2 to 6. The cumulative production of the inhibitory substance in CFS was studied, and it showed that the secretion of the inhibitory substance was initiated in middle log phase of growth and peaked in late log phase. Further, CFS synergized the activities of ciprofloxacin, moxifloxacin, and streptomycin as evaluated in terms of checkerboard titrations. It lowered the minimum inhibitory concentration (MIC) of ciprofloxacin by almost 30 times and MIC of both moxifloxacin and streptomycin by 8 times. Interestingly, pepsin treatment of CFS caused the complete abrogation of its synergistic effect with all the three antibiotics. Thus, from the study, it can be concluded that probiotic-based alternative therapeutic regimen can be designed for the treatment of P. aeruginosa infections.
authors.affiliation: Department of Microbiology, Guru Nanak Dev University, Amritsar, 143005, India, kaursukhraj@rediffmail.com.
authors.forename: Sukhraj
authors.initials: S
authors.lastname: Kaur
authors.forename: Preeti
authors.initials: P
authors.lastname: Sharma
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D055598:Chemical Phenomena; D002939:Ciprofloxacin / Q000494:pharmacology; D017077:Culture Media, Conditioned / Q000494:pharmacology*; D004269:DNA, Bacterial / Q000235:genetics; D004357:Drug Synergism; D005260:Female; D024841:Fluoroquinolones / Q000494:pharmacology; D006358:Hot Temperature; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007778:Lactobacillus / Q000502:physiology*; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D010447:Peptide Hydrolases / Q000737:chemistry*; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D017422:Sequence Analysis, DNA; D013307:Streptomycin / Q000494:pharmacology; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000517:prevention & control; D014621:Vagina / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D017077:Culture Media, Conditioned; D004269:DNA, Bacterial; D024841:Fluoroquinolones; D002939:Ciprofloxacin; D010447:Peptide Hydrolases; D000077266:Moxifloxacin; D013307:Streptomycin